1. Molina Healthcare Inc (MOH)
MOH stock makes up around 38% of Michael’s Burry’s portfolio right now, claiming he is happy with the company amidst the dip it’s taken. This position is a clear contrarian play as despite the near term earnings growth being poor, analyst sentiment seems to be improving as this stock’s valuation continues to get lower and lower (PE of 7.7 at the time of writing). And while its net income has certainly waned recently, it’s important to note that top line revenue continues to climb reliably and is forecasted to continue to do so – leaving room for Molina to turn some of that into net profit going forward. We have rated this as a medium risk, high reward stock given it’s fair debt levels (97% Debt to Equity) and great revenue growth forecasts relative to it’s current valuation. We have this rated as a HOLD right now.
2. Lululemon Athletica Inc (LULU)
LULU stock currently occupies 26% of Michael’s portfolio after significantly adding to this position in late 2025. Lululemon as seen it’s valuation slide consistently since it’s high in 2021 thanks to investor concerns surrounding demand; even though it’s revenue is still growing at impressive numbers, having seen it beating all 4 of it’s last earnings estimates. With a PE of 12 and fair revenue growth estimates, it appears Lululemon could be undervalued if they continue putting up earnings beats in 2026. We put this as a medium risk, high reward stock and also rate this a HOLD as we would like to see higher earnings estimates and more beats before upgrading.
3. SLM Corp (SLM)
SLM Corp makes up about 20% of his portfolio right now, and has also seen him bolster this position in late 2025. Like others on this list, this stock trades at a low PE (7.7 time of writing) with analyst sentiment and guidance starting to improve. We are starting to see earnings and revenue growth improve after a recent dip alongside a recent earnings beat, indicating that good things may be on the horizon for SLM if they can keep up this momentum. We put this as high risk, medium reward and have this rated as a SELL right now despite Michael Burry’s bullish position.
4. Bruker Corp (BRKRP)
Bruker currently makes up about 19% of his portfolio. With a Price to Sales of around 1.8 the valuation is certainly a bit on the lower side, we’re seeing analysts post pretty high EPS growth numbers of about 14% YOY for December 2026. This low valuation, high growth combination should be extremely attractive to fundamental investors looking to capitalize on a possible market mis-pricing. Critics may point out the risk involved with being exposed to the science industries – but the fact Bruker remains on the manufacturing side significantly reduces its reliance on groundbreaking tech and research, leaving most of the risk up to the companies buying Bruker products. Because of this, we put Bruker as a medium risk, high reward play at this time with no official WSX rating
